in several types of endocrine cancers through a variety of mechanisms ( Lima et al . 2017 ). Metastasis in adrenocortical carcinoma (ACC): do paradigms apply? ACC is a rare endocrine malignancy with a high risk of relapse and
Search Results
Enzo Lalli and Michaela Luconi
S G Creemers, P M van Koetsveld, F J van Kemenade, T G Papathomas, G J H Franssen, F Dogan, E M W Eekhoff, P van der Valk, W W de Herder, J A M J L Janssen, R A Feelders, and L J Hofland
Introduction Adrenocortical carcinoma (ACC) is a rare malignancy, with an estimated incidence of 0.7–2.0 cases per million population each year ( Kebebew et al . 2006 , Golden et al . 2009 , Fassnacht et al . 2013 , Kerkhofs et al
Ziwei Zhang, Menglian Li, Jianjun Wang, Mengsi Liu, Huan Chen, Yuan Lou, Yijie Wang, Qi Sun, Dalong Zhu, Ping Li, and Yan Bi
Introduction Adrenocortical carcinoma (ACC) is a rare and highly aggressive malignancy with an annual incidence of 0.7–2.0 cases per million population ( Crona & Beuschlein 2019 ). ACC has a dismal prognosis, with a 5-year survival ranging
Michaela Kuhlen, Pascal Mier, Marina Kunstreich, Lienhard Lessel, Dominik Schneider, Ines Brecht, Denis M Schewe, Michael C Frühwald, Peter Vorwerk, and Antje Redlich
Introduction Adrenocortical carcinomas (ACC) in children and adolescents are rare endocrine tumours with highly aggressive behaviour and dismal prognosis. The only curative treatment option is complete surgical tumour removal, while the role
Isobel C Mouat, Kei Omata, Andrew S McDaniel, Namita G Hattangady, Debnita Talapatra, Andi K Cani, Daniel H Hovelson, Scott A Tomlins, William E Rainey, Gary D Hammer, Thomas J Giordano, and Tobias Else
with PA have a benign adrenal adenoma or bilateral hyperplasia. Adrenocortical carcinoma (ACC), however, is a very rare cause of increased aldosterone levels, and a recent literature review identified only 58 reported patients ( Seccia et al . 2005
Linus Haberbosch, Lukas Maurer, Arvid Sandforth, Charlotte Wernicke, Joachim Spranger, Knut Mai, and Reiner Jumpertz von Schwartzenberg
Introduction Adrenocortical carcinoma (ACC) is a rare endocrine tumor characterized by high recurrence rates and often-fatal prognosis. The overall 5-year survival of patients undergoing tumor surgery is believed to be less than 40
Yunhui Cheng, Raili Emilia Kerppola, and Tom Klaus Kerppola
order to develop such compounds for therapeutic use, it is essential to determine their efficacy in cell and animal models of cancer and to characterize their molecular mechanisms of action. Adrenocortical carcinoma (ACC) is an aggressive disease with
Meenu Jain, Lisa Zhang, Mei He, Ya-Qin Zhang, Min Shen, and Electron Kebebew
Introduction Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy of the adrenal cortex ( Favia et al . 1995 , Wajchenberg et al . 2000 , Icard et al . 2001 , Bilimoria et al . 2008 ). Prognosis is poor in patients with locally
Constanze Hantel, Sara Jung, Thomas Mussack, Martin Reincke, and Felix Beuschlein
Introduction Adrenocortical carcinoma (ACC) represents a rare but highly malignant tumor entity. In a large proportion of cases, the high growth rate of this endocrine neoplasm results in late diagnosis not amendable to surgical resection. However
Peter M van Koetsveld, Giovanni Vitale, Richard A Feelders, Marlijn Waaijers, Diana M Sprij-Mooij, Ronald R de Krijger, Ernst-Jan M Speel, Johannes Hofland, Steven W J Lamberts, Wouter W de Herder, and Leo J Hofland
Introduction Adrenocortical carcinoma (ACC) is a rare but highly malignant endocrine tumor. Surgery is the primary choice of treatment but recurrence rates after surgery are high ( Schteingart et al . 2005 , Fassnacht et al . 2011 ). In case of